The age range of the control group was 34 13
Several GLS inhibitors have been developed, among which CB-839 is currently undergoing clinical trials as a potent, orally bioavailable GLS-selective inhibitor for the treatment of various cancers, including TNBC, NSCLC, and colon cancer (NCT03057600, NCT03057600, NCT03057600, NCT03057600, NCT03057600, NCT03057600)
Putnam JB, Jr, Robersonan SL, Lewin S, Correa AM, Swisher SG , Walsh GL, Rice DC, Vaporciyan AA, Roth JA, Smythe WR
The full gradient programme for both pumps and switching times for the six-port valve are summarised in the Supplement (Table S1)
fights urban skin problems (stress, pollution, glycosylation)
This often results in poor drug loading and requires the use of ionic surfactants that can irritate the ocular surface [353, 354]